NIH Axes Funding for Fetal Tissue Research from Abortions, But Not Miscarriage Cases
The National Institutes of Health (NIH) has announced that it will no longer fund research using human fetal tissue obtained from "elective" abortions. The decision marks a significant shift in the agency's stance on funding, following years of efforts by anti-abortion advocates to restrict such research.
Under the new policy, NIH-funded projects involving fetal tissue from elective abortions are expected to cease immediately. However, researchers will still be able to use tissue obtained from miscarriages, a practice that is often considered less reliable due to potential genetic or chromosomal abnormalities.
The move has sparked mixed reactions in the scientific community, with some hailing it as a modernization of the agency's research priorities and others expressing concern about the implications for medical breakthroughs. According to the NIH, the number of agency-backed projects involving fetal tissue from abortions had declined significantly since 2019, from $60 million invested in 77 projects last year.
The decision reflects ongoing tensions between anti-abortion groups and researchers who rely on fetal tissue to advance our understanding of diseases such as diabetes, Alzheimer's, and infertility. Fetal tissue has also played a crucial role in the development and production of vaccines for various illnesses.
While some have welcomed the move as an effort to reflect "the best science of today" and the values of the American people, others fear that it may hinder progress in medical research and limit access to life-saving treatments.
The National Institutes of Health (NIH) has announced that it will no longer fund research using human fetal tissue obtained from "elective" abortions. The decision marks a significant shift in the agency's stance on funding, following years of efforts by anti-abortion advocates to restrict such research.
Under the new policy, NIH-funded projects involving fetal tissue from elective abortions are expected to cease immediately. However, researchers will still be able to use tissue obtained from miscarriages, a practice that is often considered less reliable due to potential genetic or chromosomal abnormalities.
The move has sparked mixed reactions in the scientific community, with some hailing it as a modernization of the agency's research priorities and others expressing concern about the implications for medical breakthroughs. According to the NIH, the number of agency-backed projects involving fetal tissue from abortions had declined significantly since 2019, from $60 million invested in 77 projects last year.
The decision reflects ongoing tensions between anti-abortion groups and researchers who rely on fetal tissue to advance our understanding of diseases such as diabetes, Alzheimer's, and infertility. Fetal tissue has also played a crucial role in the development and production of vaccines for various illnesses.
While some have welcomed the move as an effort to reflect "the best science of today" and the values of the American people, others fear that it may hinder progress in medical research and limit access to life-saving treatments.